Use of Active Surveillance vs Definitive Treatment Among Men With Low- and Favorable Intermediate-Risk Prostate Cancer in the US Between 2010 and 2018

Bashir Al Hussein Al Awamlh; Daniel A Barocas; Alec Zhu; Jeffrey J Tosoian; Lee Ponsky; Serban Negoita; Jonathan E Shoag

doi:10.1001/jamainternmed.2022.7100

Use of Active Surveillance vs Definitive Treatment Among Men With Low- and Favorable Intermediate-Risk Prostate Cancer in the US Between 2010 and 2018

JAMA Intern Med. 2023 Jun 1;183(6):608-611. doi: 10.1001/jamainternmed.2022.7100.

Authors

Bashir Al Hussein Al Awamlh¹, Daniel A Barocas¹, Alec Zhu², Jeffrey J Tosoian¹, Lee Ponsky³, Serban Negoita⁴, Jonathan E Shoag^{2

3}

Affiliations

¹ Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.
² Department of Urology, New York-Presbyterian Hospital, Weill Cornell Medicine, New York, New York.
³ Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.
⁴ Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.

No abstract available

Plain language summary

This cross-sectional study of data from the Surveillance, Epidemiology and End Results database assesses temporal trends in the use of active surveillance and watchful waiting vs definitive treatment in men with low- and favorable intermediate–risk prostate cancer in the US between 2010 and 2018.

MeSH terms

Humans
Male
Neoplasm Grading
Prostate-Specific Antigen
Prostatic Neoplasms* / therapy
Watchful Waiting*

Substances

Prostate-Specific Antigen